Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
About this item
Full title
Author / Creator
Publisher
US: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
US: Oxford University Press
Subjects
More information
Scope and Contents
Contents
Abstract
We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alo...
Alternative Titles
Full title
Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7888564
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7888564
Other Identifiers
ISSN
2328-8957
E-ISSN
2328-8957
DOI
10.1093/ofid/ofab050
